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ABSTRACT
With many safety and technical limitations partly
mitigated through chemical modifications, antisense
oligonucleotides (ASOs) are gaining recognition as
therapeutic entities. The increase in potency real-
ized by ‘third generation chemistries’ may, however,
simultaneously increase affinity to unintended tar-
gets with partial sequence complementarity. How-
ever, putative hybridization-dependent off-target ef-
fects (OTEs), a risk historically regarded as low, are
not being adequately investigated. Here we show
an unexpectedly high OTEs confirmation rate during
screening of fully phosphorothioated (PS)-LNA gap-
mer ASOs designed against the BACH1 transcript.
We demonstrate in vitro mRNA and protein knock-
down of off-targets with a wide range of mismatch
(MM) and gap patterns. Furthermore, with RNase
H1 activity residing within the nucleus, hybridization
predicted against intronic regions of pre-mRNAs was
tested and confirmed. This dramatically increased
ASO-binding landscape together with relatively high
potency of such interactions translates into a consid-
erable safety concern. We show here that with base
pairing-driven target recognition it is possible to pre-
dict the putative off-targets and address the liability
during lead design and optimization phases. More-
over, in silico analysis performed against both pri-
mary as well as spliced transcripts will be invaluable
in elucidating the mechanism behind the hepatoxic-
ity observed with some LNA-modified gapmers.
INTRODUCTION
The elegant and conceptually simple mechanism of RNase
H1-mediated gene knockdown has long been viewed
as having great therapeutic promise. By establishing
an ‘antagonistic-like’ effect on a given target, antisense
oligonucleotides (ASOs) have the potential to selectively
target the entire transcriptome, with relatively short de-
sign and optimization cycle times. Therapeutic ASOs are
not, however, without their shortfalls and challenges, some
of which include safety concerns. Hybridization-dependent
toxicities, i.e. those driven by Watson–Crick base-pairing,
are perhaps unique to ASOs and short interfering RNAs
(siRNAs) in terms of underlying mechanism. It has been
well reported that siRNAs can be relatively non-selective,
owing to their ability to exert ‘microRNA-like’ effects on the
3′ UTR of mRNAs with limited sequence complementarity
(1). For ASOs, far less has been published on hybridization-
dependent OTEs (2,3), although it has not generally been
viewed as a major issue. The Oligonucleotide Safety Work-
ingGroup (OSWG) ‘letter to the editor’ published inNature
Biotechnology in 2012 (4) however clearly recommends as-
sessment of OTEs for ASOs during drug discovery and de-
velopment, both computationally and experimentally.
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The molecular characteristics and downstream effects of
ASOs are, however, significantly altered by a wide range
of chemical modifications to the backbone, heterocycle or
sugar moieties of the oligonucleotide. The vast majority
of antisense therapeutics in clinical development contain
a phosphorothioate (PS) backbone modification (5), which
by increasing systemic stability and protein binding (relative
to the naturally occurring phosphodiester backbone), im-
proves the pharmacokinetic and pharmacodynamic prop-
erties of ASOs. However, the so-called ‘first generation’ (i.e.
containing fully-PS backbones) ASOs have a poor thera-
peutic index and a number of class toxicities were identified.
These have been extensively reviewed byHenry et al. (6) and
predominantly involve hybridization-independent mecha-
nisms (e.g. accumulation-driven degenerative changes in the
kidney proximal tubules, antagonism of receptors of the
innate immune system and immunostimulatory effects, co-
agulopathy, complement activation in the non-human pri-
mate). Hybridization-dependent toxicities are also a risk
for the class though they may arise through exaggerated
primary pharmacology, in a similar manner to that ob-
served with some small molecule drugs. Although theo-
retically possible, this has not been reported as a signifi-
cant issue with first generation ASOs (6). Subsequent ‘sec-
ond generation’ modifications such as 2′-O-methoxyethyl
(2′ MOE) (7) have enhanced potency (due to greater binding
strength) and in vivo stability relative to the first generation
ASOs (8,9). Certain aspects of the PS ASO class toxicities
were partly mitigated by the incorporation of these mod-
ifications, e.g. complement activation in non-human pri-
mate and immunostimulatory effects in rodents are gener-
ally reduced (10). These modifications were, however, not
compatible with RNase H1 cleavage activity. This limita-
tion was overcome by using the so-called ‘gapmer’ strategy
(11), where aDNA/PS ‘core region’, acting as anRNaseH1
substrate, is flanked by ‘wings’ of modified nucleotides that
increase affinity and stability. More recently bicyclic nu-
cleotide modifications have been developed and are gener-
ally referred to as ‘third generation chemistries’. The locked
nucleic acid (LNA) and constrained ethyl (cEt) modifi-
cations, developed independently by the groups of Jesper
Wengel/Takeshi Imanishi, and by Isis Pharmaceuticals re-
spectively (12–14), fall within this category. These modifi-
cations markedly increase binding energy/potency for the
intended target, enabling the design of shorter ASO se-
quences (15). This has the potential to enhance in vivo de-
livery and can further mitigate some of the typical class
effects of PS-containing ASOs (e.g. shorter ASOs have a
reduced potential for complement activation) (16,17). On
the other hand, by decreasing the sequence length it be-
comes increasingly more challenging to identify a unique
target site. Furthermore, increased binding energy has the
capacity to not only increase potency against the intended
target, but also to ‘off-targets’. As the binding affinity is
increased and classical toxicities are eliminated through
increasingly advanced oligonucleotide chemical modifica-
tions, hybridization-mediated off-target effects (OTEs) may
become a more prevalent concern.
Following delivery into the cells, it was found that ASOs
can shuttle between cytoplasm and nucleus in a process sim-
ilar to active transport for oligonucleotide classes with a PS
backbone, and by diffusion for unmodified oligonucleotides
(18). The RNase H1 enzyme, initially reported to be present
throughout the cell (3,19), was recently shown to be active
mainly in the nucleus and to a lesser extent in mitochondria
(20). The activity of ASOs in the nucleus is well documented
with studies such as those showing intronic (21) and nuclear
(22) RNA knockdown, or those based on alternative splic-
ing by steric hindrance (23).We hypothesized that ASOs are
as likely, if not more so, to interact with intronic sequences
as with exonic regions. However, hybridization-dependent
intronic OTEs, to our knowledge, have not been explored
forRNaseH1-utlizingsASOs. The sheer length of unspliced
transcripts, and potentially less stable secondary structure,
in theory increase the probability of finding a potent hit.
This should be as applicable to unintended ‘off-target’ in-
teractions as intended ones.
The phenomenon of off-target RNA effects should be
viewed as analogous to secondary pharmacology for small
molecule drugs (i.e. interacting with unintended proteins
or receptors). Pharmaceutical companies often character-
ize this potential during early lead optimization by assess-
ing binding against related targets, or those that are known
to carry a significant safety liability, with a view to pro-
gressing leads with the greatest overall selectivity. One of
the unique opportunities of ASO-based therapeutics is that
putative off-target interactions can be predicted using se-
quence alignment algorithms. In this study, a number of 16
nt long, PS-LNA-containing ASO gapmers were designed
and screened against the BACH1 transcript. A list of puta-
tive intronic and exonic OTEs was generated for each ASO
with corresponding high level target annotation. A small
panel of potential unintended interactions was selected and
prioritized based on Gene Ontology terms and literature
review. These were verified in vitro in cells known to ex-
press both the intended target and off-target mRNAs using
standard quantitative polymerase chain reaction (qPCR).
The effect of targeting intronic regions was examined at the
mRNA, rather than the pre-mRNA, level to capture the
downstream effect of the cleavage event. This was followed
up by a more extensive evaluation of a single lead using a
medium-throughput qPCR method (OpenArray). To rule
out the potential of false positive effects being generated
by ASO-mediated qPCR interference, a subset of OTEs
were confirmed by branched DNA assay (bDNA) and im-
munoblotting. A correlation between binding strength of
ASO–RNA target sequence and corresponding knockdown
potency was also evaluated to examine the contribution of
affinity to observed effects. This thorough approach was
used to examine the occurrence, potency and patterns of




The LNA-PS ASO gapmers were designed and supplied
by Exiqon, Denmark A/S (Vedbaek, Denmark) as >85%
pure. The sequence specificity consideration at the design
phase followed the common practice of selecting leads with
least number of potential interactions with mature, messen-
ger RNA, at the perfect or near perfect level. Six distinct
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BACH1-targeting ASOs were selected (Table 1) based on in
vitro pharmacology screening of 130 and 30 leads in Hu-
man Lung Adenocarcinoma Epithelial (A549) and Normal
Human Bronchial Epithelial (NHBE) cells respectively. The
ASOs were fully phosphorothioated, contained between
five and six LNA nucleotides and had 5-methylcytosine
incorporated into CpG motifs. Additionally, a BACH1-
targeting siRNAwas used to verify that the observed OTEs
were not a consequence of downstream effects following
BACH1 knockdown. Both ASO and siRNA knockdowns
were normalized to corresponding Random Sequence Con-
trols (RSC) which were designed with matching modifica-
tion type.
Off-target effect prediction
To secure a high sensitivity of putative off-target detection,
an implementation of rigorous Needleman–Wunsch algo-
rithm (24) was selected and optimized. The alignment scor-
ing system and sensitivity parameters were modified based
on the length of the query ASO and database size. The ge-
nomic database was constructed using Ensembl’s gene an-
notation repository (based on GRCh37 human assembly
from the Genome Reference Consortium) (25). All non-
functional (pseudo) genes were removed. The prediction re-
sults were further filtered, to discard hits that did not reach
a set similarity threshold (at least 75% overlap with ASO
sequences). The putative off-targets were annotated with
reported cellular function (Ensembl, NCBI, WikiGenes),
cell and tissue expression (eGenetics (26), Institute of the
Novartis Research Foundation (GNF) (27) and in-house
datasets) and Gene Ontology terms. Representative genes
were selected following a manual, non-clinical safety pro-
file review and assessment of the sequence identity relative
to the ASOs (to ensure that a wide range of alignment pat-
terns were represented). The sequence identity of represen-
tative predicted OTEs that were investigated in this study
are listed in Tables 2–4. To facilitate the viewing of results,
for OTE genes predicted to interact with ASOs at multiple
sites, only the ‘top’ hit, with relatively highest sequence iden-
tity is shown. However, an additive or synergistic effect of
more than one interaction site should not be discounted. In
the case of OTEs such as with PHF6 or RAD51B, two po-
tential interactions are listed as it was difficult to prioritize
one over the other.
Cell culture and transfection
The human biological samples were sourced ethically and
their research use was in accord with the terms of the in-
formed consents. NHBE cells derived from two donors were
purchased fromLonza andmaintained inBronchial Epithe-
lial Cell Growth Medium (BEGM) (Lonza). Human lung
carcinoma cells (A549) were purchased from ATCC and
maintained in Dulbecco’s Modified Eagle Medium (Gibco)
supplemented with 10% fetal bovine serum, glutamine and
penicillin/streptomycin. The ASO concentration used in
each study was determined based on the cell type and ex-
perimental methodology. Cells were cultured in BDBiocoat
Collagen I flasks (Becton Dickinson) and were not used be-
yond third passage. Once confluent, cells were seeded into
collagen coated well plates (96 well––12 000 cells per well,
plates fromGreiner Bio-one; 12well––200 000 cells per well,
plates from Becton Dickinson; 6 well––300 000 cells per
well, plates from Greiner Bio-one) and incubated for 24
h before transfection. For gymnotic (unassisted) transfec-
tions, the desired ASO concentration was prepared in an-
tibiotic free medium (100 l per well for 96-well plates and
2 ml per well for 6- and 12-well plates). The solution was
added to cells which were then incubated for 48 h. ASO con-
centrations of up to 50 Mwere used in gymnotic transfec-
tion experiments in NHBE cells. There was good tolerabil-
ity based on an absence of a concentration-dependent re-
duced housekeeper signal and visual inspection of the cells
during the study (data not shown). We have routinely as-
sessedASOs at 50Mand above in a range of cells types us-
ing gymnosis and observed no notable effects on cell health
based on a range of cytotoxicity endpoints (see ‘Results’
section for exemplar ASOs in Supplementary Figures S1
and S2). Lipofectamine 2000 (Invitrogen) was used for as-
sisted transfections in 96-well plates. Oligonucleotides were
diluted to the required concentration to a total volume of
10 l per well and mixed with 10 l of transfection com-
plex (0.5l Lipofectamine 2000 and 9.5l of antibiotic and
serum free media). After 20 min incubation, 80 l of an-
tibiotic free medium was added to the solution and mixed.
After removing the medium from the wells, 100 l oligonu-
cleotide:transfection agent solution was added to the cells
and incubated for 24 h. Experiments were repeated at least
twice and dose-response curves were generated based on at
least six ASO concentrations and plotted using quadratic
polynomial function.
Transcript quantification
After the incubation period the medium was removed,
cells were washed with phosphate-buffered saline
(Sigma) and lysed using Promega SV RNA Lysis Buffer
(Promega) or Buffer RLT (Qiagen) supplemented with
-mercaptoethanol (Promega). Total RNA was extracted
using SV 96 Total RNA Isolation System (Promega)
using Biomek 3000 automation workstation or RNeasy
kit (Qiagen) using Qiacube robot (following the man-
ufacturer’s protocol). cDNA synthesis was performed
using a High Capacity cDNA Reverse Transcription Kit
(Applied Biosystems), according to the manufacturer’s pro-
tocol. qPCR experiments were performed on an Applied
Biosystems 7900HT System for standard qPCR (Taqman
with FAM/TAMRA probes) and QuantStudio 12K Flex
Real-Time PCR Platform for medium-throughput qPCR
with OpenArrays. Primer and probe information are listed
in Supplementary Tables S1 and S2 for standard qPCR
and OpenArray respectively. Glyceraldehyde 3-phosphate
dehydrogenase (GAPDH) and -actin (ACTB) were used
as housekeeper genes for standard qPCR normalization
and each data point was based on a measurement from
six–eight biological replicates. For OpenArray experiments,
four housekeeping genes (GAPDH, ACTB, RPLP0 and
B2M) were used and eight data measurements taken, corre-
sponding to two biological replicates for two donors, with
two technical replicates per donor. Experiments were per-
formed using protocols provided by Life Technologies. In
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Table 1. Sequences of ASO and siRNA oligonucleotides used in this study
Oligonucleotide ID Sequence (5′ -> 3′)
LNA
content Description
GSK2910546A TCAGTTTAGCAGTGTA 5 Human BACH1 targeting (ASO)
GSK2910557A AGTGTGATGAAAAGCA 6 Human BACH1 targeting (ASO)
GSK2910579A GGTCATATGTGTGTAA 5 Human BACH1 targeting (ASO)
GSK2910594A ATCGTTTCCAATTTCC 5 Human BACH1 targeting (ASO)
GSK2910613A GAGTTATTACTAGAGT 6 Human BACH1 targeting (ASO)
GSK2910632A TGAGAAGATCCATAGC 6 Human BACH1 targeting (ASO)
RSC ASO TGGGCGTATAGACGTG 4 Random sequence control (ASO)
GSK2328969A AUUUGAACCUUUAAUUCAG Human BACH1 targeting (siRNA, antisense strand)
RSC siRNA AAUUAUCCAUACAAUAUAC Random sequence control (siRNA, antisense strand)
The ASOs were fully phosphorothioated and had 5-methylcytosine incorporated into CpG motifs.
short, each cDNA sample was combined with 2× TaqMan
OpenArray Real-Time PCR Master Mix (Life Technolo-
gies) and loaded into custom designed OpenArray plates
using a QuantStudio 12K flex AccuFill system. The Ope-
nArrays were covered with immersion fluid (using reagents
from QuantStudio 12K flex OpenArray accessories kit,
Life Technologies) and loaded into the QuantStudio
12K flex instrument for RT-qPCR cycling. Samples were
subjected to standard thermal cycling protocol provided
by Life Technologies. Expression data from qPCR and
OpenArray was normalized to corresponding housekeepers
and logged before calculating the RNA level relative to
control treatment. One way analysis of variance was used
to calculate statistical significance of the treatment results.
Statistical evaluation and plotting of data was performed
in R software environment. Non-amplification based,
branched DNAmethod was performed by Axolabs GmbH
(Kulmbach, Germany) according to the manufacturer’s
protocol (Panomics).
Western blotting
Transfected cells were washed with cold Dulbecco’s
Phosphate-Buffered Saline (DPBS) (Life Technologies),
treated with Radio-Immunoprecipitation Assay (RIPA)
Buffer (Sigma) supplemented with Protease and Phos-
phatase Inhibitors (100X) (Sigma) and incubated for 30
min at 4◦C. The cells were then centrifuged for 5 min at
3000 rpm. Bicinchoninic Acid (BCA) Protein Assay Kit
(Pierce) was used to estimate total protein concentration in
cell lysates––10 g of protein was loaded in each well us-
ing Blue Loading Buffer (30X,NewEnglandBiolabs), DTT
(30X) and XP Magic Marker (0.35 l, Invitrogen). Sam-
ples were run on NuPAGE Novex 4–12% Bis-Tris Protein
Gel (Life Technologies) at 130V (constant) using Bio-Rad
Trans-Blot Semi-Dry (SD) Transfer Cell (0.8 mA/cm2, 44
mA for 90 min). Membranes were blocked with 5% milk
powder for 1 h and incubated overnight at 4◦C and 1 h at
room temperature for primary and secondary antibodies
respectively. Quantification was performed using Odyssey
Imaging System (Li-COR). NuPAGETris-Acetate Gel with
HiMarkTM Pre-stained Protein Standard (Invitrogen) and
15 instead of 10 g of sample was used for USP9X protein
due to its size (290 kDa). The signal ratio between protein
of interest and -actin was calculated for each of the wells.
Results were averaged across four biological replicates and
expressed as a percentage change relative to control treat-
ments with RSC ASO. Detail information in regards to an-
tibodies used in the study is listed in Supplementary Table
S3.
Binding affinity
ASO and target RNAoligonucleotides were diluted in a 100
mMNaCl/100 mM sodium phosphate/0.1 mM ethylenedi-
aminetetraacetic acid (EDTA) buffer to a 10 ng/l concen-
tration, and mixed in a 1:1 ratio. EvaGreen dye (Biotium)
was prepared in 1× Tris EDTA (TE) buffer (final concen-
tration of 3 M), mixed in 1:1 ratio with the duplex so-
lution and transferred to a white 384-well plate (10 l per
well). The plate was sealed with adhesive tape, centrifuged
briefly at 2500 rpm and placed into aRoche LightCycler 480
II. The melting temperature (Tm) analysis was carried out
using the protocol described in Supplementary Table S4,
whichmeasures fluorescence at 465–510 nmwith both ‘Max
Peaks (two or less)’ and ‘SYBR Green I format’ options
turned on. This producedmelt peaks (based on the first neg-
ative derivative of the melt curves) and Tm values for each
sample. The average Tm of an ASO/RNA duplex was de-
termined fromaminimumof four replicates per experiment,
and the experiment was repeated a minimum of three times.
The list of oligonucleotide sequences corresponding to pre-
dicted off-target binding sites is shown in Supplementary
Table S5.
RESULTS
Modified ASOs efficiently silence both exonic and intronic
off-targets with a wide range of mismatch/gap patterns
The prioritization and selection of putative OTEs was
based on sequence alignment, mismatch pattern and re-
view of high level information regarding the function of
the encoded protein. A range of hits including near per-
fect matches against introns and reduced sequence simi-
larity matches against exons were selected to initially ex-
plore the extent of unintended interactions for six BACH1-
targeting ASOs. Predicted interaction sites together with
their flanking regions (100 bp up- and downstream) were
avoided when selecting primer/probe binding sites to mit-
igate potential qPCR interference. Primers were also de-
signed to encompass all known splice variants. For each
tested OTE a dose-response curve was generated to calcu-
late EC50 value. To eliminate the potential for transfection
 at Im
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Figure 1. Representative qPCR results from NHBE cells gymnotically transfected with BACH1 targeting oligonucleotides; GSK2910632A (A) and
GSK2910557A (B). Dose response curves were generated for on- (BACH1) and off-target genes predicted for a particular ASO. Oligonucleotide con-
centration ranged from 0.1 to 5 M, each data point was derived from six biological replicates and ASO treatments were normalized to the non-targeting
control (RSC ASO). Additional experiments were performed in an alternative cell line (A549) to examine knockdown kinetics at 2, 4, 6, 8 and 24 h after
transfection. GSK2910632A [(C) 1 nM, (E) 10 nM] and GSK2910557A [(D) 1 nM, (F) 10 nM] were delivered to the cells using Lipofectamine 2000 and
the knockdown of on-target and selected OTEs (relative to RSC ASO) was measured at the stated time intervals. Each data point was derived from two
biological replicates and ASO treatments were normalized to the non-targeting control (RSC ASO). Sequence identity and target type information are
included in the corresponding legend figures and are also listed in Table 2. ‘MM’ stands for mismatch, whereas ‘G’ stands for gap.
agents complicating data interpretation, gymnotic transfec-
tion was used across the majority of experiments. Although
gymnotic transfection is much less efficient than assisted
transfection (we typically observe approximately three logs
difference in EC50), it has been reported to be a ‘cleaner’
system and possibly more reflective of in vivo activity (28).
The initial, small scale qPCR study in NHBE and A549
cells showed surprisingly high numbers of confirmed OTEs
with potent, reproducible knockdown (representative re-
sults in Figure 1). The investigation revealed efficient silenc-
ing of hits predicted against both exonic and intronic re-
gions, with a wide range of mismatch and/or gap patterns.
Surprisingly, even a transcript with a low sequence identity
(PHF6, 4 nt central gap against exon and three mismatches
against intron), showed an EC50 of 2 M (maximum 64%
knockdown) as compared to the on-target knockdown
of 0.3 M (Figure 1B). A time course experiment re-
vealed varying knockdown kinetics forGSK2910632A- and
GSK2910557A-mediated OTEs. While USP9X and TLE3
showed similar dose response to the on-target BACH1
 at Im
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GSK2910546A Exon RIF1 2MM aTGTGaCGATTTGACT 56% 0.001 NP
Exon TPX2 2MM AtGTGACGATTTGAcT 35% 0.0007 61%
Intron ADK 1MM ATGTGACGATTTgACT 33% 0.006 51%
Intron RUFY3 1G Oligo ATGTGACGA-TTTGACT 49% 0.0003 NP
GSK2910557A Exon TMX2 2MM AcGAAAaGTAGTGTGA 16% 0.01 47%
Intron PHF6 3MM ACGAAAAgTAGtGTgA 64% 9.8E-05 72%
Exon PHF6 4G Oligo ACGAAA- - - -AGTAGTGTGA
GSK2910632A Exon USP9X 1G Oligo CGAT-ACCTAGAAGAGT 75% 4.2E-06 83%
Exon SRRM2 2MM CgAtACCTAGAAGAGT 38% 0.002 NP
Intron TLE3 1MM CGAtACCTAGAAGAGT 31% 0.0001 48%
Intron RAD51B 1G Oligo CGATACCTA-GAAGAGT 77% 1.8E-05 NP
Intron RAD51B 2MM CGaTACCTAgAAGAGT
Dose response curves were generated from NHBE cells, gymnotically transfected with specified ASO and incubated for 48 h before lysis. Maximum knockdown was derived from the highest silencing
efficiency observed in a dose response curve (0.1–5 M for qPCR, 0.01–50 M for bDNA). NP stands for ‘not performed’. A number of OTEs listed below were predicted to interact with the ASOs at
more than one site––only the ‘top’ interaction is reported except in cases where it is challenging to select the best alignment (e.g. PHF6 and RAD51B). Within the sequence alignment column, ‘lower case’
represents a mismatch and a ‘hyphen’ represents a gap.
knockdown (with USP9X eventually showing greater activ-
ity than BACH1) (Figure 1C and E), PHF6 andAR showed
delayed kinetics and required a 10 nM dose to match the
on-target knockdown (Figure 1D and F). Several comple-
mentary approaches were undertaken to build confidence
in the initial findings; multiple regions per gene were se-
lected as binding sites for qPCR amplification, alternative
cDNA amplification methods were compared and activity
was verified in a second cell line (A549) (Figure 1C–F).
In each assay, both reproducibility and potency of the ob-
served OTE knockdown was further confirmed. To com-
pletely rule out any potential ASO-mediated qPCR arte-
fact or bias, a branched DNA assay was performed for
a selection of OTEs by Axolabs GmbH (Kulmbach, Ger-
many). The transfection conditions mirrored those used in
the qPCR study, though the knockdownwas evaluated with
higher maximum dose (5 versus 50 M). The bDNA results
(Table 2) confirmed all OTEs identified in the initial study.
OTEs are sequence-specific, mediated through RNase H1
mechanism and reflected at the protein level
To differentiate between real OTEs and downstream ef-
fects caused by target knockdown or potential ASO
class toxicity, we cross-checked the knockdown of off-
targets in cells treated with a single siRNA and three
LNA-ASOs molecules (GSK2910579A, GSK2910594A
and GSK2910632A), all designed against BACH1 (Figure
2A). The tested oligonucleotides were not predicted to share
any OTEs interactions. While all molecules showed potent
knockdown of BACH1, off-target silencing was only visible
with ASOs predicted to include such interactions (marked
with an arrow). Similar validation was carried out in the
vast majority of our assays and results always confirmed
that OTEs are sequence specific and not caused by BACH1
knockdown or an ASO class effect. Two exploratory assays
were set up to investigate the nature of the mechanism be-
hind the OTE silencing. Firstly, transcript regions up (5′)
and downstream (3′, Splice Junction) of the predicted cleav-
age site were chosen as binding sites for qPCR amplifica-
tion (Figure 2B and C). With every OTE checked, there
was good concordance between all the measurements, re-
gardless of primer location. It can thus be assumed that the
mechanism is based on full transcript degradation (exerted
through RNase H1) rather than steric blocking of splic-
ing (which could lead to aberrant, mis-spliced transcripts).
Secondly, we examined if the observed off-target transcript
knockdown resulted in a decrease in corresponding pro-
tein abundance. Western blotting was performed for PHF6
for GSK2910557A and USP9X for GSK2910632A (Figure
2D) as representative interactions. Protein levels were quan-
tified and compared against non-targeting control treat-
ments. With both OTEs, a substantial protein knockdown
was observed just 48 h after gymnotic transfection. The
confirmed off-target interactions were thus shown to be
sequence-specific and leading to degradation of entire tran-
script and consequent protein knockdown.
Intronic regions are markedly more susceptible to ASO-
silencing than exonic sequence
With the majority of the molecules being de-prioritized af-
ter the first round analysis, a more extensive follow-up as-
sessment of larger numbers of putative off-targets was con-
ducted using a reduced number of ASOs. The choice of the
OTEs was based on an early safety-based literature review
and more diverse sequence alignments with an exploratory
aim in mind. Following the high confirmatory rate in the
initial study and wide range of hits predicted against such
regions, we focussed more heavily on putative intronic hits.
Again, the sequence-specific nature of these interactions
was demonstrated with the inclusion of both a RSC control
and by evaluating the same off-targets in cells transfected
with an alternative BACH1 ASO, not predicted to have the
same interactions (data not shown). The percentage knock-
down and therapeutic index, an approximate fold difference
between the EC50 of intended therapeutic target (BACH1,
0.3 M) and given OTE, are listed in Table 3.
A range of exonic hits with 2MM or 1MM and 1 gap
showed lower confirmatory rates andmodest potency (TI>
100). For intronic hits however, we observed a much higher
confirmatory rate, with some achieving very high potency
(MAGI2, HDAC9, LARP1B, FBXW11 and FGF5). The
measured difference in interaction suggests that intronic re-
gions are more efficiently targeted and cleaved (summarized
in Figure 3). This is especially visible with MAGI2 which
showed 90% knockdown at all tested ASOs concentrations
(0.3–50 M), though the transcript showed low baseline
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Figure 2. (A) On-target (BACH1) and selected exonic (FAM156A, USP9X) and intronic (RALA) OTE knockdown were tested with siRNA and ASO
molecules designed against BACH1 but not predicted to share any OTE interactions. NHBE cells were transfected using Lipofectamine 2000 at 100
nM for siRNAs and 20 nM for ASOs, incubated for 24 h and lysed. Molecules predicted to interact with a particular gene are marked with an arrow
above the corresponding column. Each column is derived from six biological replicates and normalized to corresponding RSC (siRNA or ASO), with
error bars depicting standard error of the mean (SEM). Off-target knockdown was tested using qPCR primers designed against region upstream (5′) and
downstream (3′, across Splice Junction) of the predicted ASO:OTE interaction site. Both exonic (USP9X) (B) and intronic (TLE3) (C) OTEs predicted for
GSK2910632A were tested with two primer sets in gymnotically transfected NHBE cells (0.3–50 M). All measurements are derived from six biological
replicates and were normalized to RSCASO controls of corresponding concentrations. Primer details are listed in Supplementary Table S1. (D) Abundance
of PHF6 (left) and USP9X (right) proteins were quantified in samples treated with GSK2910557A and GSK2910632A respectively. NHBE cells were
transfected gymnotically at 20 M and incubated for 48 h before lysis. The results are shown as a percentage change relative to the non-targeting control
(RSC ASO), with error bars representing SEM. Protein levels were measured in four biological replicates. Antibody details are listed in Supplementary
Table S3. A representative Western blot with corresponding quantification is shown is Supplementary Figure S3.
expression. Moreover, our assay verified knockdown at a
mature mRNA level ensuring that the ASO’s interaction
with the intron regions results in degradation of the whole
transcript. Several of the high ranking intronic hits such as
MAGI2 and HDAC9 were predicted to interact with the
ASO at multiple sites––other than the reported ‘top’ align-
ment, the hits were of lower sequence identity (2MM + 1G
or 3MM). Though the contribution of multiple sites to total
knockdown cannot be overlooked, OTEs with a single pre-
dicted cut site (FBXW11, FGF5 and TGFA) also showed
high silencing efficiency and potency. While among OTEs
tested for GSK2910546A we did not identify very potent
exonic hits, data from other leads (presented in Figures 1
and 2 and Table 4) confirmed that ASO:exon OTE inter-
actions can also lead to highly efficient silencing. Based on
the results presented here and our unpublished data, pre-
dicted exonic off-targets are however, relatively less likely to
be confirmed.
Considering the observed higher safety concern brought
by unintended interaction between ASOs and intronic re-
gions (Table 3), an additional study was performed to more
comprehensively evaluate knockdown potential for intronic
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Table 3. Results from medium-throughput qPCR study (OpenArray) performed on NHBE cells by unassisted transfection with GSK2910546A
Target
region OTE name Top sequence identity Top sequence alignment
Max. Kd.
(qPCR, 50 M) EC50 (M)
Therapeutic
index (fold)
Exonic RIF1 2MM aTGTGaCGATTTGACT 56% 31 >100
EMB 2MM aTGTGACGATtTGACT 36% >50 >100
TPX2 2MM AtGTGACGATTTGAcT 28% >50 >100
KCTD6 2MM ATGTgACGATTTgACT No Activity
TMEM185B 2MM ATGTGACGATTtGAcT No Activity
CDH26 2MM ATGTGACGATTtGaCT No Activity
NBAS 2MM ATGTGACGATtTgACT No Activity
UPF1 1MM + 1G Oligo AtGTGACGATTT-GACT 30% >50 >100
LAMA2 1MM + 1G Oligo ATGT-GACGATTTGACt No Activity
VTCN1 1MM + 1G Oligo ATGT-GACGATTTGAcT No Activity
IL36RN 1MM + 1G Oligo ATGT-GACGATTTgACT No Activity
KBTBD3 1MM + 1G Oligo ATGTgACGAT-TTGACT No Activity
MOSPD2 1MM + 1G Oligo ATGTgA-CGATTTGACT No Activity
ZNF782 1MM + 1G Oligo ATgTGACG-ATTTGACT No Activity
Intronic MAGI2 1MM AtGTGACGATTTGACT 90% <0.3 <1
HDAC9 1MM ATGTGACGAtTTGACT 86% 1.2 4
LARP1B 1MM ATGTGACgATTTGACT 80% 3.5 11
SLC12A2 1MM ATGTGACGATTTgACT 45% >50 >100
COG5 1MM ATGTGACGATtTGACT 40% >50 >100
ZNF385B 1MM ATGTGACGATTTGAcT Possible Activity ∼100
VNN2 1MM ATGTGACgATTTGACT No Activity
GOT2 1G Target ATGTGAcGATTTGACT No Activity
FBXW11 2MM aTGTGACGATTTGACt 97% 0.3 Equipotent
FGF5 2MM aTgTGACGATTTGACT 83% 3.5 11
TGFA 2MM atGTGACGATTTGACT 75% 10 33
SCAPER 2MM ATGTGACGATTTGAct 40% >50 >100
Dose response curve (0.3–50 M) was generated for each off-target based on eight data measurements, corresponding to two biological replicates for two donors, with two technical replicates per donor.
The data was normalized using four housekeepers (GAPDH, ACTB, PRLP0 and B2M) and calculated relative to RSC ASO. Primers and probes were pre-designed by Life Technologies, with corresponding
assay IDs listed in Supplementary Table S2. Therapeutic Index shows approximate fold difference in EC50 between the intended (BACH1, 0.3 M) and specified OTE (e.g. 10 M/0.3 M = TI of 33.3).
Within the sequence alignment column, ‘lower case’ represents a mismatch or a gap in the target, a ‘hyphen’ represents a gap within the ASO sequence. Only the ‘top’ (i.e. of highest sequence identity)
interaction is reported per OTE.
Figure 3. Graphical summary of 26 OTEs predicted and tested for
GSK2910546A. Total (A), exonic (B) and intronic (C) OTEs are grouped
by their potency relative to EC50 of intended target (BACH1, 0.3 M).
Data is derived fromOpenArray results presented in Table 3.While among
the exonic OTEs tested for GSK2910546A few showed high potency, re-
sults from other leads (Figures 1 and 2 and Table 4) confirmed that inter-
actions with exonic regions can also lead to highly potent knockdown.
OTEs with two mismatches. A panel of 33 off-target genes
predicted for GSK2910546A was chosen, encompassing a
wide range of mismatch positions. The predictions were
evaluated by unassisted transfection in NHBE cells based
on a 10 point dose response curve. While the baseline ex-
pression for 10 genes was too low to obtain valid results,
of the remaining 23 off-targets, several showed very po-
tent knockdown (Table 4). Knockdown was also measured
with alternative ASO that was not predicted to share any
OTE interaction (data not shown). Whilst it is challenging
to draw definitive patterns due to relatively small datasets
and variable mechanistic aspects (accessibility, transcript
abundance, exposure time in the nucleus), it is clear that
for a 16 mer LNA-gapmer, OTEs with 2MM are still a sig-
nificant concern. The alignment patterns of highest rank-
ing off-targets (FBXW11, TIAM2, POU2F1 and ZNF674)
suggest that mismatches at the terminal positions appear to
be particularly well tolerated. Based on the results shown
in Tables 2–4, LNA-PS ASO gapmers are able to tolerate
mismatches across their entire length, regardless of whether
they appear within the DNA core or in the ‘wings’.
Potency of OTEs is highly correlated with binding affinity
between ASO and the target sequence
The presence of a mismatch or gap between ASO and the
sequence of an off-target transcript reduces the affinity be-
tween the potential duplex, and is one of the key factors
which determines the potency of knockdown. The affinity
can be characterized through Tm, which is the tempera-
ture at which half of the oligonucleotides are in a single-
stranded form, while the remaining half are forming a du-
plex. Several assays have been developed to experimentally
measure the Tm of oligonucleotide duplexes. The original
approach which used ultraviolet-visible (UV) spectroscopy
is relatively low-throughput and requires significant quanti-
ties of oligonucleotides. Fluorescence-based assays are now
more commonly used to measure nucleic acid hybridiza-
tion, as these are more amenable to high-throughput anal-
ysis. The majority of such methodologies employ the use of
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Table 4. Summary of knockdown results for 2MM intronic OTEs predicted for GSK2910546A
Target Top sequence alignment
Max. Kd.
(qPCR, 50 M) EC50 (M)
Therapeutic
index (fold)
BACH1 Perfect Match - Exon 95% 0.6 On-Target
FBXW11 aTGTGACGATTTGACt 97% 0.3 <1
TIAM2 aTGTGACGATTTGACt 97% 0.4 <1
POU2F1 aTGTGACGATTTGACt 95% 0.5 <1
BBS9 aTgTGACGATTTGACT 95% 0.4 <1
ZNF674 aTGTGACGATTTGACt 86% 0.5 <1
AP3B1 aTgTGACGATTTGACT 84% 4.4 7
FGF5 aTgTGACGATTTGACT 89% 5.3 9
RIC8B ATgtGACGATTTGACT 76% 5.3 9
PRICKLE1 aTGTgACGATTTGACT 63% 18 29
TBCK aTGtGACGATTTGACT 63% 21 36
SPATS2L AtGTGACGATTTGACt 71% 36 60
SCAPER aTGTGAcGATTTGACT 53% 38 63
SCAPER ATGTGACGATTTGAct
RBMS3 aTGTGACGATTTGAcT 52% 49 81
NRF1 aTGTGACgATTTGACT 48% ∼50 ∼94
FUT8 ATGTGaCgATTTGACT 32% >50 >100
VPS13C ATgTgACGATTTGACT 31% >50 >100
USP45 aTGTGACGATTTGAcT 26% >50 >100
FRS2 ATgTGACgATTTGACT 21% >50 >100
MEIS2 ATgTGACGATTtGACT 18% No Activity
RBFOX2 ATGtgACGATTTGACT 18% No Activity
PTPRK aTGTGACgATTTGACT 17% No Activity
PTPRK aTGTGACgATTTGACT
*XRRA1 1 Gap Target - Intron 98% 0.5 <1
*GNL3 2 Mismatches - Exon 82% 7.8 13
Mature mRNA knockdown was measured in NHBE cells transfected gymnotically for 48 h with a 10-point dose range (with six biological replicates).
Therapeutic Index was calculated against the EC50 of on-target gene (BACH1, 0.6M)which was measured alongside the OTEs. To facilitate classification
of low potency OTEs (i.e. maximal knockdown observed in dose response curve lower than 45%), we set a threshold of 20% below which the hit is no longer
viewed as active and placed in the ‘No Activity’ category. Higher dose points are required to fully evaluate such hits and to accurately fit a dose response
curve. Two genes (*XRRA1 and *GNL3) which were initially predicted as 2MMOTEs, were subsequently found to have different alignments in the newer
release of genomic sequence and coordinate databases. ASO alignment against SCAPER and PTPRK genes showed two independent alignments against
intronic regions at 2MM level. Within the sequence alignment column, ‘lower case’ represents a mismatch.
a fluorophore dye and a quencher, which are attached to
oligonucleotides. Denaturation of a nucleic acid duplex is
coupled to the separation of the two probes, which results in
a change of fluorescent signal (29–31). The approach does,
however, require expensive labeled probes. As an alternative,
a high-throughput method was developed which is based
on an intercalating EvaGreen dye (Biotium), which fluo-
resces when bound to a double-stranded nucleic acids (e.g.
ASO/RNA duplex). Although the mean Tm values were
slightly lower when measured with the EvaGreen dye than
by UV spectroscopy, results from both methods showed
very high correlation (Pearson’s r = 0.98, P = 0.0032)
(Supplementary Figure S4, protocols for both methods are
shown in Supplementary Table S4).
To explore the extent to which binding affinity alone may
influence off-target activity, the binding strength between
GSK2910546A and its on- (16 nt long perfectly comple-
mentary RNA sequence) and nine off-target sites (16 nt
long RNA sequence corresponding to predicted target re-
gions of 2MM OTEs) were analyzed using the EvaGreen
fluorescence assay (sequences are listed in Supplementary
Table S5). The decrease in Tm between fully complemen-
tary ASO–RNA duplex and ASO–2MM RNA duplexes
varied between 4.2 and 11.6◦C (Figure 4), although we
have seen as little as 1.6 degree difference with RNA se-
quence which was initially predicted as a putative target site
within XRRA1 gene (2MM, AUCACUGCUAAACUGA,
data not shown). In general, a very high correlation was ob-
served betweenmeasured Tm and percentage knockdown (r
= 0.84,P-value= 0.0025). Themost potent off-target activ-
ity observed was with those targets which retained the high-
est affinity for the ASO based on Tm. However there were
outliers, which may indicate that some regions are more ac-
cessible to the ASO than others (context not evaluated in
these analyses). For example, TBCK has similar affinity to
ASO compared to FBXW11 but there is a 70-fold difference
in their potency.
DISCUSSION
The gapmer design of ASOs relies on the activity of RNase
H1 to achieve gene knockdown following hybridization
to the target transcript. RNase H1 activity occurs mainly
within the nucleus (20) and there are numerous examples of
interaction between ASOs and non-coding sequences (e.g.
splice modulating therapeutics, intron or enhancer RNA
targeting ASOs) (32,33).While ASOs interact with all RNA
species, both spliced and unspliced, the concept does not ap-
pear to have been considered when assessing potential off-
target interactions of RNase H1-utilizing ASOs. Specificity
evaluations were historically performed exclusively against
mature, mRNA sequence. Using a more thorough bioinfor-
matic approach for our BACH1 targeting LNA-gapmers, a
large number of potential off-target transcripts with partial
homology to the ASOs were identified. These included be-
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Figure 4. Correlation between Tm of ASO-target sequence duplexes and
in vitro knockdown levels of corresponding genes (r = 0.84, P-value =
0.0025). The binding affinities between RNA sequences (listed in Supple-
mentary Table S5) and GSK2910546A was measured using EvaGreen dye,
following the protocol shown in Supplementary Table S4. The difference
in Tm between fully complementary duplex (intended target, BACH1) and
ASO-2MMRNA duplexes varied between 4.2 and 11.6◦C, although it can
be as low as 1.6 degrees (initially predicted 2MM target site withinXRRA1
gene, data not shown).
tween one and three mismatches in both exon and intron
sequence and gaps in either the ASO or target sequences.
While a relatively smaller number of non-coding RNA hits
were also predicted, this study focussed on protein coding
transcript as a proof of concept.
The extensive length of intronic regions translates into
a substantial number of putative off-target predictions,
though the efficiency of such hits was unknown.While iden-
tifying putative ASO interactions is relatively straightfor-
ward, no general method has been established to accurately
predict the efficiency of on- or off-target knockdown, equiv-
alent to those created for siRNAs (34). Our initial studies
showed that interaction with both exonic and intronic re-
gions (Figure 1) could lead to potent off-target hits. These
results were confirmed using a number of techniques to
rule out interference by the LNA-gapmer in the cDNA
synthesis or qPCR assay (Table 2). Furthermore protein
knockdown was demonstrated for a small number of con-
firmed off-targets (Figure 2D). After initially confirming
the intron-based OTEs (Figure 1), a more thorough investi-
gation was performed on higher numbers of predicted hits
(with GSK2910546A, Table 3). While exon hits showed a
relatively modest confirmatory rate (Figure 3B), active in-
tron off-targets were abundant and inmany cases highly po-
tent (Figure 3C). Subsequent studies showed that of 21 pu-
tative intronic off-targets with two mismatches, 12 showed
significant levels of mRNA knockdown following gymnotic
delivery, with five displaying knockdown activity equivalent
(or higher) to the on-target.
The potency, confirmation rate and breadth of mismatch
and/or gap pattern of OTEs verified in our study is be-
yond anything previously reported in the literature. The
main safety challenges have historically been attributed to
hybridization-independent effects such as interaction with
proteins (35) and Toll-like receptors of the innate immune
system (36). While potent chemistries (such as, but not lim-
ited to, LNA) bring significant improvement to efficacy
(32), there is a clear potential for these molecules to in-
teract with transcripts that share complete or partial com-
plementarity. Previous reports with earlier generations of
ASO chemistry showed a decrease in activity against the tar-
get sequence with 1MM and essentially no activity with 2
(2,21) or 3 MM both in vitro and in vivo (3). These stud-
ies were, however, limited in scope, with very few targets
and mismatches only being incorporated into a small num-
ber of the possible positions in the ASO/target duplex. The
suggested improved mismatch discrimination brought by
LNAs was mostly based on studies performed in the con-
text of using LNA-oligos as hybridization probes (37,38)
rather than as LNA-gapmers. The ASO-gapmer ability to
distinguish between single nucleotide polymorphisms (39)
appears to be limited tomismatches around the target cleav-
age site. Another study on the specificity of LNA-gapmers
(40) reported reduced activity with 1MM and no activ-
ity with 2MM. As before, the conclusion was based on
a very low sample size and small panel of mismatch po-
sition combinations. Furthermore, the mismatched ASOs
have only been tested against a target region with the same
accessibility. Our analysis (not shown) suggests that ac-
cessibility is one of the main determinants of ASO activ-
ity and can greatly affect the results. Moreover, position
of the mismatch will affect both the affinity for the target
RNA (Tm) and also interactions with RNase H1 enzyme.
The introduction of mismatches into a MOE-gapmer has
in some instances increased target RNA cleavage rate in a
cell-free RNase H1 cleavage assay (41). Given the surpris-
ingly high potency of 2MM hits (Table 4), it would be in-
teresting to verify whether mismatches can affect the LNA-
ASO:target:RNase H1 structure in a way that increases the
cleavage efficiency.
Our data shows that with a fully phosphorothioated 16
mer format (containing 5–6 LNAs) a wide range of pat-
terns and mismatches can be tolerated. This is most likely
due to compensation, as the remainingmatched nucleotides
exert high enough binding energy to maintain the interac-
tion. This was confirmed in the binding assay (Figure 4),
where experimentally measured Tm of ASO–OTE target
sequence duplexes highly correlated with in vitro knock-
down levels of a corresponding off-target genes (r= 0.84,P-
value = 0.0025). We have also observed examples of OTEs
with similar Tmbutmarkedly different potency (TBCKand
FBXW11), which underlines the likely importance of tar-
get site accessibility. In the context of shorter LNA probes,
mismatches are more detrimental to the stability of the
oligo:target duplex (38) though it has not been defined if
this translates to decreased knockdown rates and potency
versus off-targets in an LNA-gapmer context. Based on un-
published initial in-house data, we found that shorter gap-
mers have their own set of challenges. A number of 14 mer
ASOs (containing 3–5 LNAs) covering a range of predicted
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Tm were designed against a second target and tested in
vitro. Though some significant interactions do still occur,
in general the confirmation rate of hits with 2MMs was re-
duced when compared to the 16 mer format (unpublished
data). Unfortunately the confirmation rate and potency of
OTEs with 1MM was considerable, with the EC50 values
in some cases exceeding that of our intended target by sev-
eral fold. While shorter ASOs can accommodate less mis-
matches and gaps, it is markedly more difficult to design a
potent molecule while maintaining high specificity. Given
the significant detrimental effect on the silencing efficiency
brought by decreasing theASObinding energy, it seems that
with current technology certain potency:specificity trade-
offs have to be accepted. Compounds with lower binding
strength (e.g. with low modification content or less potent
chemistry) would require a higher dose to establish a thera-
peutic effect, increasing the likelihood of encountering typ-
ical oligonucleotide class toxicities and possibly OTEs.
We observed that the scale of liability markedly differed
from one ASO sequence to another, with a few designs
showing relatively low confirmatory rates. It is possible that
a certain combination of ASO length, gap size, sequence
and positioning of chemically modified bases affect duplex
stacking and increase tolerance formismatches.Muchmore
data is however needed to comprehensively explain the dif-
ference in OTEs liability and introduce a framework for de-
sign.Given the observed tolerance formismatches and gaps,
combined with confirmation of intron-OTEs and the sheer
length of unspliced transcripts, it is very difficult to design
a potent OTE-free lead, certainly for ASOs of ≤16 nt in
length with currently available chemistries.
While both intronic and exonic off-targets can lead to po-
tent knockdown, the clear differences in their confirmation
rate (Figure 3) raises questions in regards to the cleavage
event. As the RNase H1 enzyme is not capable of differ-
entiating between coding and non-coding regions, the phe-
nomenonmust be driven by divergence in themolecular ‘en-
vironment’ between those sequence types. With the activity
of cleavage occurring mainly in the nucleus (20), the length
of time between the target being fully transcribed to themo-
ment it is transported to the cytoplasm will affect ASO ac-
tivity. The concept was particularly well demonstrated with
a nuclear-retained transcript with expanded CUG repeats,
which showed unusual sensitivity to RNase H1-mediated
knockdown (42). Longer ‘exposure’ resulting from slower
transcription, longer gene or target position (closer to the
end of transcript or within 3′ UTR) would however, con-
tribute equally to both regions. Additionally, as the introns
are spliced out, exons would have the advantage of a longer
‘activity window’ in the nucleus. This would be expected to
result in exonic hits exhibiting a higher overall confirma-
tory rate, which we have not observed in this study. With
pre-mRNA structure shifting alongside transcription (43)
and most likely being local (44), co-transcriptional acces-
sibility could in theory encompass a stage of a more fa-
vorable structural variant for ASO binding. This concept
was used to improve the in silico design of exon skipping
oligonucleotides (43) but fails to explain the difference in
observed confirmatory rate and potency between intronic
and exonic targeting hits.We have observed examples where
different accessibility most likely accounts for the differ-
ences in off-target activity, e.g. in the case of BBS9 and
FGF5 which both have two mismatches in the same posi-
tion but differ by almost 12-fold in EC50. The most likely
explanation thus, lies in the different sets of RNA-binding
proteins/other RNAs, ‘shielding’ those regions and affect-
ing their secondary structure. With the co-transcriptional
targeting of intronic regions and consequent depletion of
mature transcript being confirmed, we can also safely as-
sume that exonic regions can interact with ASO at both the
unspliced as well as spliced RNA stage. This creates a ques-
tion on the proportion of knockdown of ‘mature RNA’ tar-
gets such as BACH1 that is achieved by cleaving the tran-
script during and after transcription and splicing. The ra-
tio is most likely determined by the time it takes for RNA
to reach a mature stage and the time between reaching this
stage and being exported from the nucleus.
Although the above mentioned characteristics of intron
regions are a major hurdle to ASO specificity, they could
also bring significant advantages to the therapeutic field.
Several of the randomly selected intronic OTEs showed
lower EC50s than our intended target (Tables 3 and 4), even
though the six exon-targeting leads were among the most
potent sequences in an in vitro pharmacology screening of
130 ASOs. The confirmation rate of the intron targets was
also much higher relative to exonic hits (Figure 3). Design-
ing ASOs specifically against intron regions might provide
more potent molecules that would attain therapeutic effect
with fewer chemical modifications (i.e. fewer LNAs) or at
a lower dose. This in turn could reduce potential OTEs or
class toxicities that are only observed at higher dose and/or
binding strength. The efficiency of such ASOs is highly
dependent on several intron characteristics (intron length,
transcription time, size of gene, splicing pattern of entire
transcript) and hence not all genes would be appropriate
for such a strategy.
Our data demonstrate that a thorough OTEs assessment,
utilizing both in silico predictions and in vitro confirmation
in relevant cell lines, is a crucial aspect of lead optimiza-
tion for RNase H1 recruiting ASOs. In terms of discharging
and/or managing the risk around confirmed OTEs, there
are a number of approaches that can be implemented.As ex-
pression of a given transcript varies greatly between differ-
ent cells and tissues (45), it is tempting to de-prioritizeOTEs
based on their baseline expression levels. Whether this is a
viable method depends on many factors such as route of
administration, chemical modifications used or distribution
to unintended organs/cells, especially those showing high
levels of ASO accumulation (46). Based on sequence align-
ment the putative interactions should be examined and if
verified, an EC50 established. Where there is a large sep-
aration in EC50s of the intended and unintended targets,
this will build confidence that there is unlikely to be any
safety-related consequence in vivo. Where significant activ-
ity versus an OTE is confirmed, a risk assessment may be
necessary, which would include a literature-based review of
the known (and theoretical) consequences to health of in-
hibiting the off-target gene. This paper-based exercise may
discharge any risk or identify opportunities to do so exper-
imentally. For certain OTEs with a theoretical safety lia-
bility, it may not always be possible to discharge the risk
in vitro. For OTEs that have an ortholog sequence in an-
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imal models and show high sequence identity for the tar-
get region, any potential liability may be discharged by the
lack of anticipated adverse effect observed in in vivo safety
studies, or at least through demonstrating acceptable mar-
gins. It is also advantageous to design leads with perfect
sequence complementarity against an ortholog (if any) of
the intended target, to test the efficacy in an in vivo model.
It also has to be noted that organism-specific toxicities are
possible and OTEs predictions should be made separately
for each animal model species.
Our study clearly demonstrates that hybridization-
mediated OTEs are a significant concern for ASOs contain-
ing modifications that markedly increase binding energy
(e.g. bicylic chemistries). Additional studies based on leads
of varying chemical composition will help to determine
whether the observed mismatch tolerance is a general prop-
erty of ASO gapmers and to what extent the phenomenon
is affected by structural changes brought by the various
modifications. Critically, the confirmation rates and aver-
age potency of effect versus intronic regions were generally
higher than for exonic hits, underscoring the importance of
considering these off-targets in any such analyses. Impor-
tantly, these effects were measured at the mature mRNA
level and also translated into protein knockdown when as-
sessed. The overall selectivity does appear to vary from
one ASO to another, making it possible to identify 16 mer
LNA-PS ASO leads for progression with a relatively low
potential for OTEs. A judicious computational and experi-
mental analysis during lead development appears to be the
best route to selecting molecules with lowest overall poten-
tial for hybridization-mediated OTEs and minimizing the
likelihood of development failure and patient risk. A com-
prehensive computational pipeline (‘RNArcher’) geared to-
ward development of ASO gapmers with minimized OTEs
liability will bemade available in the near future.Whether or
not a given off-target interaction is acceptable or not should
eventually be based on a risk:benefit analysis. It should
also be remembered that hybridization-mediated OTEs for
ASOs are analogous to secondary pharmacology targets for
small molecules. With the former we are in the unique posi-
tion of being able to predict those interactions, whereas for
the latter in the main we are ignorant. The inclusion of in-
tronic regions in OTE prediction can not only improve the
selectivity of designed and progressed leads, it might also
explain some of the LNA–ASO-mediated toxic phenotypes
reported in the literature (47,48). Based on the compari-
son between exonic and intronic OTEs we also believe that
designing RNase H1-utilizing ASOs specifically against in-
trons, while highly influenced by intron characteristics and
the splicing mechanism, has the potential to improve ther-
apeutic index and possibly safety.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
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